BioCorRx Submits Expanded Access Treatment Protocol to FDA for BICX104, Implantable Biodegradable Naltrexone Pellet for Treatment of Opioid Use Disorder
BioCorRx
ANAHEIM, CA, Aug. 15, 2023 (GLOBE NEWSWIRE) — via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”) today announced its submission to the US Food and Drug Administration (FDA) of an expanded access program application for BICX104 (implantable naltrexone pellet) for the treatment of opioid use disorder (OUD) patients that meet program eligibility criteria.
BioCorRx Announced Interim Positive Safety and Pharmacokinetic Results of Phase 1 Clinical Trial at 4th Annual NIH HEAL Initiative Investigator Meeting
BioCorRx
BioCorRx Inc. (OTCQB: BICX) (the “Company”), a clinical-stage developer and provider of innovative treatment programs for substance use and related disorders, has announced interim positive safety and pharmacokinetic (PK) results for the Phase I clinical trial of the Company’s BICX104 implantable naltrexone pellet.
BioCorRx Submits Fast Track Application to FDA for BICX104, an Implantable Biodegradable Naltrexone Pellet for The Treatment of Opioid Use Disorder
BioCorRx
ANAHEIM, CA, July 18, 2023 (GLOBE NEWSWIRE) — via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced the submission of a fast track application to the U.S. Food and Drug Administration (“FDA”) for BICX104, an implantable biodegradable naltrexone pellet for the treatment of opioid use disorder (OUD).
BioCorRx Announces Completion of Treatment Phase of Study Subjects and Preliminary Safety Data from Phase I Clinical Trial of BICX104, an Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder
BioCorRx
BICX104 is a biodegradable, long-acting subcutaneous pellet of naltrexone for the treatment of OUD being developed with the goal of improving patient compliance to naltrexone therapy compared to other marketed pharmacotherapies.
BioCorRx Completes Final Subject Enrollment in Phase I Clinical Trial of BICX104, an Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder
BioCorRx
BioCorRx Inc., a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced that the last subject has been enrolled in the Phase I clinical trial of BICX104, an implantable biodegradable naltrexone pellet for the treatment of opioid use disorder.
Researchers Developing Implant To Fight Alcohol, Opioid Addiction
Newsy
You might know Jeremy Miller from the ’80s family sitcom “Growing Pains.” But it’s the pains of addiction that he wants to share now. “Even on the show, I never had it together,” he said. Miller has a family medical history of alcohol use disorder on both sides. He began drinking at a very young age.
‘Growing Pains’ star Jeremy Miller drank a ‘half pint of vodka’ and got a DUI during low point of addiction
Fox News
“Growing Pains” actor Jeremy Miller shared one of his rock bottom points of his battle with alcoholism from years ago when he was pulled over for driving under the influence after drinking a “half pint of vodka” and getting behind the wheel.
BioCorRX Inc. Discusses BICX104 Human Trials and 2B3D Metaverse Partnership with The Stock Day Podcast
Stock Day Media
The Stock Day Podcast welcomed BioCorRx Inc. (OTCQB: BICX)(“the Company”), an addiction treatment solutions company offering a unique approach to the treatment of substance use and other related disorders. CEO and CFO of the Company, Lourdes Felix, joined Stock Day host Everett Jolly.
BioCorRX Inc. Discusses BICX104 Human Trials and 2B3D Metaverse Partnership with The Stock Day Podcast
Bloomberg
The Stock Day Podcast welcomed BioCorRx Inc. (OTCQB: BICX) (“the Company”), an addiction treatment solutions company offering a unique approach to the treatment of substance use and other related disorders. CEO and CFO of the Company, Lourdes Felix, joined Stock Day host Everett Jolly.
OC firm fighting addiction seeks volunteers for clinical trial
The Orange County Register
Sure, you’ve heard that drug- and alcohol-related deaths soared during the pandemic, but the impact on children — who should be going to Scout meetings and soccer games, play practice and karate class — is truly stupefying. From 2019 to 2020 in Orange County, drug and alcohol deaths among kids aged 10-17 exploded by 800%. From 2020 to 2021, they shot up another 122%.
Rewiring Your Medication
RadioMD
Edward Bowz, LMFT has an MA in Clinical Psychology from Phillips Graduate Institute and is the Director of Behavioral Health for BioCorRx®. He was the first mental health practitioner certified by BioCorRx to administer the BioCorRx Counseling Program consisting of their 35 Keys to Sobriety.
BioCorRx Announces First Subject Dosed in Phase I Clinical Trial of BICX104
BIOCORRX
BioCorRx Inc. today announced that the first subject has been dosed in the Phase I clinical trial of BICX104, an implantable biodegradable naltrexone pellet for the treatment of opioid use disorder (OUD), which is being developed under BioCorRx Pharmaceuticals, Inc., the Company’s controlled clinical stage pharmaceutical company.
Listen to Tom’s Podcast!
CORUZANT TECHNOLOGIES
Tom Welch is Executive Vice President at BioCorRx. Mr. Welch has decades of operating experience and was a founder and Director of Operations at TAK Management from 2012 until 2015. Mr. Welch led a team that completely reorganized clinic operations. Tom also successfully negotiated reimbursement with major private insurance corporations across the U.S.
June is PTSD Awareness Month
Tom Welch is interviewed on Fox News, representing BioCorRx’s latest efforts in new gamification therapy techniques using the MetaVerse. Watch the interview in full!
Removing the Addiction Barrier
CORUZANT TECHNOLOGIES
According to The National Health Study for a New Generation of United States Veterans — a large-scale VA health study of 60,000 Iraq and Afghanistan veterans — 13.5% of deployed and non-deployed service members screened positive for PTSD. Over 30% of these individuals reported self-medicating with drugs and alcohol, which mental health professionals note exacerbates PTSD and creates barriers to its treatment.
BioCorRx and 2B3D to Pilot First-of-its-Kind PTSD and Addiction Treatment Solutions for Veterans in Metaverse Setting
BIOCORRX
Collaboration to create a synergistic treatment offering, combining BioCorRx’s MAT treatment program and 2B3D virtual reality technology. Plans toward expanding the offering to other at-risk groups upon evaluating results of pilot with veterans.
First Trials Set to Begin for BICX104, An Unprecedented Way for Patients to Receive Naltrexone
ENTREPRENEUR MAGAZINE
According to the CDC, there were 75,673 opioid-related overdose deaths from April 2020 to April 2021, a near 20,000 increase from the 12-month period prior… But the latest news from addiction treatment solutions company BioCorRx could change the way patients and treatment providers approach the process of recovery forever.
Stay Immersed In Your Market Plan
MED TECH GURUS
In this episode, we have Ms. Lourdes Felix Chief Executive Officer and Director of BioCorRx and President of BioCorRx Pharmaceuticals Inc. Gurus Lourdes takes us down the path of why being immersed in a market plan pays huge dividends for you and ultimately the patients you help.
BioCorRx Provides Update on R&D Candidates, Mental Health Awareness and Clinical Development
SNN Network
BioCorRx Inc. (OTCQB: BICX) is an addiction treatment solutions company offering a unique approach to the treatment of substance use and other related disorders.
Tom Welch Podcast Interview
HERE’S TO YOUR HEALTH WITH JOSHUA LANE
Our guest this morning is Tom Welch and Tom Welch is the Executive Vice President of BioCorRx and they are a leading healthcare solutions company and they focus on improving the lives of those struggling with alcohol, opioid and other addictive disorders.
This new treatment may cure addiction .. any addiction
WSB-TV
A medical implant containing a time-released drug that attacks cravings from opiates, heroin and alcohol helped a local businessman break a $9,000 per month addiction to pain medication.
A year into Biden’s presidency, we’re only burying more overdose victims
THE HILL
In 1999, there were just under 20,000 fatal overdoses. Now, overdose deaths are five times higher—over 100,000 in the 12 months ending May 2021, according to the CDC’s most recent, tragically delayed, data.
The Pandemic Has Aggravated the Opioid Crisis – Is Biden’s Plan Enough to Combat It?
PHARMALIVE
The pandemic has undoubtedly altered the way of life for all Americans, but it has also shed light into the bleak statistics that are showing the opioid crisis is even worse than ever before.
‘Saved our son’s life’ — injectable pellet, fentanyl vaccine among cutting-edge addiction treatments
NEWS 5 CLEVELAND
With recent news of record-breaking drug overdose deaths across the country and in our own backyards, News 5 Investigators went searching for the cutting edge strategies in this battle against drugs.
A New Bill in Congress Designates Methamphetamines as an Emerging Threat, but is it enough?
BeatAddiction News
At an alarming pace, Meth is gaining ground on opioids as an addictive substance. Solutions could lie in some of Ohio’s recent efforts. Michael Howcroft, Pharmacy Consultant, Beat Addiction Recovery.
